

ATHENS CARDIOLOGY UPDATE 2008

The Emerging Role of Inflammation and Fibrosis in Atrial Fibrillation and the Potential of Counter Interventions

Michalis Efremidis, MD, Dimitrios Bramos, MD

*2nd Department of Cardiology
"Evangelismos" General Hospital,
Athens Greece*

Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical practice, affecting approximately 0.9% of the population.¹ The prevalence of AF is strongly age-dependent, affecting approximately 1% of persons aged 65 years and 5% of individuals older than 65 years.² AF is also associated with an increase in the relative risk of mortality ranging from 1.3 to 2.34, independent of other risk factors as well as an increasing morbidity and adversely affects quality of life.³⁻⁵ Unfortunately, current rhythm control strategies are far from ideal. Data from five comparative studies of a primary rate control vs. rhythm control strategy for patients with a history of AF failed to show a significant superiority of rhythm control.⁶⁻¹⁰ In fact, these studies merely emphasized the limited efficacy and high side-effect profile of the currently available anti-arrhythmic drugs.¹¹

INFLAMMATION AND ATRIAL FIBRILLATION

There is now an increasing body of evidence linking inflammation to a broad spectrum of cardiovascular conditions, such as coronary artery disease (CAD), insulin resistance and diabetes mellitus, and hypertension.¹²⁻¹⁶ In addition, there is emerging data to support the association between inflammation and AF.¹⁷⁻¹⁸

The pathophysiology of AF is highly complex. It is now recognized that the development of AF leads to functional changes within the atria that perpetuate the arrhythmia ('AF begets AF'), by a process known as electrical remodeling.¹⁹ Structural remodeling of the atria occurs in parallel with the changes of electrical remodeling. The structural changes that define this structural remodeling include left atrial dilatation and increasing atrial fibrosis.²⁰ Key to this fibrotic process is the deposition of increased amounts of connective tissue between individual cells and with the deposition of large amounts of collagen and fibronectin.²¹ Bruins et al. were the first to propose the inflammation-AF hypothesis, following their observations of an increased frequency of AF after coronary artery bypass surgery. They noted that the peak incidence of AF occurred on the second and third post-operative days, which coincided with the peak elevation of CRP levels.²²

Histological evidence to support the association between inflammation and AF has been derived from several sources.²³⁻²⁷ Results of atrial biopsies taken from patients in AF compared with controls have demonstrated evidence of inflammatory infiltrates and oxidative damage within the atrial tissue. The inflammatory markers that have been most frequently studied are high-sensitivity C reactive protein (hs-CRP) and interleukin (IL)-6. Levels of hs-CRP have been noted to be higher among patients with

*Address for correspondence:
E-mail: micbcar@otenet.gr*

PREVENTING AF BY MODULATING THE
INFLAMMATORY STATE

AF compared with controls in sinus rhythm. Also, persistent AF patients have higher hs-CRP levels than paroxysmal AF patients, and both have higher levels than controls.²⁸⁻³⁵ Furthermore, a longer duration of AF is associated with higher hs-CRP levels and larger left atrial dimensions, supporting a link between the burden of AF, inflammation, and structural remodelling. In both cross-sectional and longitudinal studies, hs-CRP has remained a consistent and significant predictor of early AF relapse after successful cardioversion, even after adjustment for risk factors for AF, such as hypertension and CAD. hs-CRP has also been shown to be predictive of subsequent future development of new cases of AF among a large cohort of patients in sinus rhythm.^{30-32,34} IL-6 levels would be raised in patients with AF compared with healthy controls.

There have been five studies which have investigated the relationship between IL-6 and AF. Four of these studies found increased levels of IL-6 in patients with AF compared with healthy controls, with one failing to find any association.^{28-30,35,36} So far, there has been only one study that has looked into the possible association between TNF- α and AF. This was a very small study and did not adjust for confounding factors; however, it did demonstrate increased levels of TNF- α in patients with AF compared with healthy controls in sinus rhythm.²⁸ Finally, there appears to be a relationship between elevated white blood cell count as a marker of inflammation and the development of AF after cardiac surgery in 181 consecutive patients undergoing coronary bypass or cardiac valve surgery, even after multivariate analyses.³⁷

There is histological evidence to confirm that AF (both persistent and paroxysmal) leads to altered angiotensin II receptor expression. In a key paper, Cardin et al. were able to link increased atrial expression of angiotensin II receptors with increased atrial cell death and leukocyte infiltration supporting a potential link between the RAAS, inflammation, and AF. Furthermore, there is now evidence linking polymorphisms in the renin-angiotensin system (RAS) gene with an increase risk of subsequent AF development, further supporting the role of the RAAS in the development of AF.³⁸⁻⁴³

Although there appears to be a link between inflammation and AF, one of the key questions is whether the observed inflammation in AF increases the risk of thromboembolism as has been demonstrated for atherosclerotic models. Conway et al. were the first to confirm this putative link between inflammation and complications of AF. In a small pilot study, they showed that elevated IL-6 levels were an independent predictor of the composite of stroke or death among a cohort of 77 high-risk AF patients.⁴⁴ This observation was complemented by data from Thambidorai et al. which showed that trans-oesophageal risk factors for stroke were greater for patients with elevated hs-CRP compared those with normal levels among 104 patients with AF.⁴⁵ Hence, there appears to be an established link between inflammation, AF, and thrombosis.

There have been a large number of studies that have analyzed the relationship between **RAAS inhibition and AF**. In a recent large meta-analysis (56308 patients) incorporating 11 of the 12 randomized trials using either ACE-inhibitors or ARBs for the prevention of AF, Healey et al. demonstrated a favourable effect of RAAS inhibition in the primary and secondary prevention of AF. They concluded that ACE-inhibitors/ARBs reduced the overall risk of AF by 28% [95% confidence interval (CI) 15–40%, P:0.0002] across a broad spectrum of patient subgroups (including patients with hypertension, heart failure, post-myocardial infarction, and postcardioversion). Furthermore, the reduction in AF was similar independent of whether an ACE-inhibitor or an ARB was the main drug group used (ACE-inhibitors: 28%, P:0.01; ARBs: 29%, P:0.00002).⁴⁶

There have been several putative mechanisms to explain the favourable actions of ACE-inhibitors and ARBs in the prevention of AF: decreased atrial stretch; lowered end-diastolic left ventricular pressure and subsequent left atrial pressure; the prevention of atrial fibrosis; the modification of sympathetic tone, alteration in ion currents and atrial refractoriness, and direct anti-arrhythmic effects.⁴⁷ However, given the demonstrated important role of the RAAS in inflammation and AF, it could be postulated that interruption of the RAAS may exact positive effects upon the left atrium by reducing atrial inflammation, oxidative stress, and reduce atrial remodelling.

Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, remain the most powerful and effective lipid-lowering drugs. A series of landmark clinical trials have established statins as effective agents in the primary and secondary prevention of coronary disease. It has become increasingly apparent that the benefits of statins extend to mechanisms beyond their cholesterol-reducing effects. These 'pleiotropic' (multiple) effects include improved endothelial function with increased nitric oxide bioavailability, anti-thrombotic effects, enhanced stability of the atherosclerotic plaque, and decreased oxidative stress and vascular inflammation. If AF is indeed linked to inflammation then statins would offer a potentially preventative role in AF. There have been five studies so far that have analyzed the efficacy of statins in the prevention of AF.⁴⁸⁻⁵² Four of these studies showed favourable effects of statins to reduce the incidence of AF, with only one study reporting negative results. Siu et al were the first to study the prevention of AF with statins. They retrospectively studied 62 patients with lone persistent AF lasting 3 months who underwent direct current cardioversion, and observed that statin-treated patients (n = 10) had less recurrent AF than the control group of 52 patients (40 vs. 84%, P : 0.0007); however,

this was a very small and underpowered observational study.⁵³ In a much larger observational study, Young- Xu et al. studied a cohort of 449 patients with CAD at high risk of AF. They observed a significantly lower rate of new AF development among statin users (9%) compared with non-users (15%). Of note, the potential impact of statins on AF development was independent of its cholesterol-lowering ability. Also, the efficacy of statins in preventing AF appeared to correlate with the length of statin use, with longer statin use being associated with greater protection against the subsequent development of AF.⁵⁴ In the largest study so far, Hanna et al. performed a cross-sectional analysis of 25 000 patients enrolled in the multicenter Guidant-sponsored Advancement Heart Failure Registry; of these patients, 7027 patients (27%) developed AF, and statin therapy led to a 23% reduction in AF, when compared with those not treated, even after multivariate analysis (odds ratio for AF 0.685; *P* , 0.001).⁵⁵

STEROIDS

In a double-blind study, Dernelis and Panaretou randomized 104 patients with first presentation persistent AF to low-dose glucocorticoid therapy (16 mg methyl prednisolone for 4 weeks tapered to 4 mg for 3 months) or placebo.⁵⁶ A primary rhythm control strategy involving amiodarone & cardioversion was adopted in all of the patients as part of the trial protocol. All patients were successfully cardioverted and were commenced on oral propafenone post-cardioversion. The authors found that methyl prednisolone significantly reduced the primary endpoint of AF recurrence (50% in the placebo group vs. 9.6% in the glucocorticoid group) as well as the extended endpoint of permanent AF (29% in the placebo group vs. 2% in the glucocorticoid group). In addition, hs-CRP concentrations were a significant predictor of the primary end-point, with higher hs-CRP levels being predictive of AF recurrence, and vice versa. In addition, methyl prednisolone significantly lowered hs-CRP by an average of 80% within the first month, and this reduction was maintained for the duration of the 30-month study (*P*:0.001). The authors also demonstrated that the risk of AF recurrence was increased by approximately seven times for each 1 mg/dL increase in plasma levels of hs-CRP, providing a strong link between the degree of inflammation and the burden of AF.

FISH OILS

Dietary intake of polyunsaturated fatty acids (PUFAs), notably omega (n)-3 fatty acids, have been to shown to have favourable effects on cardiovascular outcomes. Their efficacy can only be partly explained by improvement in lipid profile and there is mounting evidence to support potential anti-in-

flammatory and antioxidant properties of oily fish. Indeed, n-3 fatty acids have anti-inflammatory properties and are frequently used clinically to treat symptoms of inflammatory diseases, such as rheumatoid arthritis or Crohn's disease.^{57,58} In a prospective, population-based cohort of 4815 older (>65 years) Mozaffarian et al. demonstrated that consumption of high levels of fish containing n-3 fatty acids was associated with a lower incidence of subsequent AF development.⁵⁹ However, these results are challenged by an even larger prospective study of 47 949 participants (mean age: 56 years) which investigated the relation between the consumption of n-3 fatty acids from fish, by use of a detailed semi-quantitative food questionnaire, and risk of AF or flutter, but found that consumption of n-3 fatty acids from fish was not associated with a reduction in risk of AF or atrial flutter.⁶⁰ Finally, in a recently published study of 160 patients pre-treatment with omega-3 fatty acids reduced the incidence of AF post-coronary artery bypass surgery by 58% compared with patients treated with usual care only.⁶¹ In this study, 2 g/day of PUFAs was administered at least 7 days before surgery and continued until discharge. In addition, treatment with fish oils reduced the length of hospitalization from 8.2 to 7.3 days (*P* :0.017).

VITAMIN C

Ascorbic acid (vitamin C) is potent oxygen scavenger, which may potentially modulate the inflammatory and oxidative abnormalities associated with AF.⁶² In a novel study, Carnes et al. gave supplemental ascorbate to 43 patients before, and for 5 days following, cardiac bypass graft surgery, and found that ascorbate significantly reduced the incidence of post-operative AF (16.3% in ascorbate treated vs. 34.9% in control subjects).⁶³ They also showed that atrial peroxynitrate (a known ROS) formation was increased during rapid atrial pacing and that atrial ascorbate levels were reduced following atrial pacing. The current evidence would thus support the hypothesis that vitamin C attenuates atrial electrophysiological remodelling and reduces AF burden, possibly via the scavenging peroxynitrite and other reactive oxygen species, and reducing the inflammatory substrate.

ATRIAL FIBRILLATION AND ATRIAL FIBROSIS

Which mechanism of AF is characteristic in a setting of atrial fibrosis is unknown, as evidence exists for both reentry and discrete, stable foci as an AF mechanism in dogs with pacing-induced CHF. Li et al showed a mechanism of macroreentry with conduction abnormalities providing the milieu for AF propagation before termination with dofetilide, an IKr channel blocker. In contrast, this study also showed in a model

of rapid atrial pacing that multiple wavelets were the likely mechanism, and dofetilide was ineffective in terminating AF. The rapid atrial pacing model has atrial electrical remodeling and little in the way of structural remodeling. The CHF model does not have any significant atrial electrical remodeling (at least none that contributes substantially to the AF substrate) but has substantial atrial structural remodeling.^{64,65} Stambler et al suggested that AF in the setting of CHF in dogs was focal in origin caused by triggered activity. This triggered activity was shown to be produced by delayed afterdepolarizations initiated by intracellular Ca²⁺ overload. Drugs that reduced intracellular Ca²⁺ levels (verapamil, flunarizine, ryanodine) all terminated AF.⁶⁶ Okuyama et al performed high-density mapping of the pulmonary veins during AF in dogs with CHF. In half of the AF episodes recorded in the CHF model, focal activation was seen from within the vein independent of the LA. This type of activation was not seen in any of the AF occurring in controls, as the pulmonary veins were activated passively from wavefronts originating from the LA.⁶⁷

The precise mechanisms and signaling pathways involved in the development of atrial fibrosis are unknown. It appears, however, that the atrium is more susceptible to atrial fibrosis than is the ventricle, and currently three interrelated pathways appear to be involved the renin-angiotensin system, TGF-1, and the oxidative stress pathways.

Transgenic mouse models of angiotensin-converting enzyme (ACE) overexpression have been shown to result in atrial fibrosis.⁶⁸ Several clinical and animal studies have shown that use of ACE inhibitors with CHF reduces the occurrence of AF and AF vulnerability.⁶⁹ Use of ACE inhibitors has also been shown to prevent the progression of paroxysmal AF to chronic AF and to increase the efficacy of electrical cardioversion of AF.^{70,71} These clinical data suggest that ACE inhibitors may be useful in delaying progression of atrial fibrosis and AF.

In a transgenic mouse model that overexpresses a constitutively active transforming growth factor TGF- β 1, selective atrial interstitial fibrosis was observed, but ventricular histology was normal. This occurred despite equal overexpression of TGF-1 in the atrium and the ventricles. The increase in atrial fibrosis was shown to correspond to an increase in conduction heterogeneity and AF vulnerability.⁷² Cellular electrophysiology was not affected by the TGF- β 1. This study demonstrated that atrial fibrosis alone is a sufficient substrate for AF, and that TGF- β 1 may play an important role in the genesis of atrial fibrosis. In another study by the same group, the drug pirfenidone was used to target the expression of TGF- β 1. Pirfenidone has been shown to significantly reduce expression of TGF- β 1, with a concomitant reduction in tissue fibrosis in multiple experimental animal models.⁶⁵ Increases in AngII and activated TGF- β 1 concentrations reciprocally enhance each other's production⁷³ and induce expression of additional profibrotic molecules in fibroblasts⁷⁴ creating positive feedback cycles for fibrosis. Mechanical stretch induces collagen syn-

thesis⁷⁵ along with increased AngII and TGF- β 1 expression in cardiac fibroblasts⁷⁶, and thus chronic atrial dilation may contribute to structural remodeling and the domestication of AF.⁷⁷ Fibroblast stretch-sensing mechanisms show exquisite sensitivity, with different types of deformation causing differential ECM expression profiles. In addition to profibrotic actions, mechanical stretch of fibroblasts can directly modulate myocyte electrical activity, a potentially proarrhythmic mechanism called mechanoelectric feedback.⁷⁸

CONCLUSION

Inflammation and fibrosis play an important role in the development of AF. Therefore inflammation and fibrosis may constitute new therapeutic targets in the management of AF. More studies are needed to clarify these important issues.

REFERENCES

1. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ ESC guidelines for the management of patients with atrial fibrillation: executive summary. *Circulation* 2001;104:2118–2150
2. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population based estimates. *Am J Cardiol* 1998;82:2N–9N.
3. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. *Circulation* 1998;98:946–952.
4. Lehto M, Snapinn S, Dickstein K, Swedberg K, Nieminen MS; OPTIMAAL Investigators. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. *Eur Heart J* 2005;26:350–356.
5. Gronefeld GC, Lilienthal J, Kuck KH, Hohnloser SH; Pharmacological Intervention in Atrial Fibrillation (PIAF) Study Investigators. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation: results from a prospective randomized study. *Eur Heart J* 2003;24:1430–1436.
6. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation – pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. *Lancet* 2000;356:1789–1794.
7. Van Gelder IC, Hagens VE, Bosker HA, et al; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. *N Engl J Med* 2002;347:1834–1840.
8. Wyse DG, Waldo AL, DiMarco JP, et al; AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med* 2002; 347:1825–1833.
9. Carlsson J, Miketic S, Windeler J, et al; STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) Study. *J Am Coll Cardiol* 2003;41:1690–

- 1696.
10. Opolski G, Torbicki A, Kosior DA, et al; Investigators of the Polish How to Treat Chronic Atrial Fibrillation Study. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. *Chest* 2004;126:476–486.
 11. Boos CJ, More RS, Carlsson J. Persistent atrial fibrillation: rate control or rhythm control. Rate control is not inferior to rhythm control. *BMJ* 2003;326:1411–1412. 41.
 12. Spodick DH. Arrhythmias during acute pericarditis: a prospective study of 100 consecutive cases. *JAMA* 1976;235:39–41.
 13. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. *Circulation* 2002;105:1135–1143.
 14. Sjöholm A, Nystrom T. Endothelial inflammation in insulin resistance. *Lancet* 2005;365:610–612.
 15. Blann AD. Assessment of endothelial dysfunction: focus on atherothrombotic disease. *Pathophysiol Haemost Thromb* 2003–2004;33:256–261.
 16. Nadar S, Blann AD, Lip GY. Endothelial dysfunction: methods of assessment and application to hypertension. *Curr Pharm Des* 2004; 10:3591–3605.
 17. Silvestro A, Scopacasa F, Ruocco A, et al. Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease. *Vasc Med* 2003;8:225–232.
 18. Boos CJ, Lip GYH. The role of inflammation in atrial fibrillation. *Int J Clin Pract* 2005;59:870–87247.
 19. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. *Eur Heart J* 2005;26:2083–2092. .
 20. Wijffels MC, Kirchhof CJ, Dorland R, Allesie MA. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. *Circulation* 1995;92:1954–1968.
 21. Boldt A, Wetzel U, Lauschke J, et al. Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. *Heart* 2004;90:400–405.
 22. Kostin S, Klein G, Szalay Z, Hein S, Bauer EP, Schaper J. Structural correlate of atrial fibrillation in human patients. *Cardiovasc Res* 2002;54:361–379.
 23. Bruins P, te Velthuis H, Yazdanbakhsh AP, et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. *Circulation* 1997;96: 3542–3548
 24. Nakamura Y, Nakamura K, Fukushima-Kusano K, et al. Tissue factor expression in atrial endothelium associated with non-valvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. *Thromb Res* 2003;111:137–142.
 25. Verheule S, Wilson E, Everett T IV, et al. Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation. *Circulation* 2003;107:2615–2622.
 26. Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. *Circulation* 2001;104:174–180.
 27. Kamiyama N. Expression of cell adhesion molecules and the appearance of adherent leukocytes on the left atrial endothelium with atrial fibrillation: rabbit experimental model. *Jpn Circ J* 1998;62:837–843.
 28. Frustaci A, Chimenti C, Bellocci F, et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. *Circulation* 1997;96:1180–1184.
 29. Sata N, Hamada N, Horinouchi T, et al. C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? *Jpn Heart J* 2004;45:441–445.
 30. Conway DS, Buggins P, Hughes E, Lip GY. Predictive value of indexes of inflammation and hypercoagulability on success of cardioversion of persistent atrial fibrillation. *Am J Cardiol* 2004;94:508–510.
 31. Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. *J Am Coll Cardiol* 2004;43:2075–2082.
 32. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. *Circulation* 2003;108:3006–3010.
 33. Dernellis J, Panaretou M. C-reactive protein and paroxysmal atrial fibrillation: evidence of the implication of an inflammatory process in paroxysmal atrial fibrillation. *Acta Cardiol* 2001;56:375–380.
 34. Chung MK, Martin DO, Sprecher D, et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. *Circulation* 2001; 104:2886–2891.
 35. Watanabe T, Takeishi Y, Hirono O, et al. C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fibrillation. *Heart Vessels* 2005;20:45–49
 36. Roldan V, Marin F, Martinez JG, et al. Relation of interleukin-6 levels and prothrombin fragment 1 ω 2 to a point-based score for stroke risk in atrial fibrillation. *Am J Cardiol* 2005;95:881–882.
 37. Psychari SN, Apostolou TS, Sinos L, et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. *Am J Cardiol* 2005;95:764–767.
 38. Abdelhadi RH, Gurm HS, Van Wagoner DR, Chung MK. Relation of an exaggerated rise in white blood cells after coronary bypass or cardiac valve surgery to development of atrial fibrillation postoperatively. *Am J Cardiol* 2004;93:1176–1178.
 39. Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. *J Am Coll Cardiol* 2000;35:1669–1677.
 40. Boldt A, Wetzel U, Weigl J, et al. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. *J Am Coll Cardiol* 2003;42:1785–1792.
 41. Cardin S, Li D, Thorin-Trescases N, et al. Evolution of the atrial fibrillation substrate in experimental congestive heart failure:

- angiotensin-dependent and -independent pathways. *Cardiovasc Res* 2003;60:315–325.
42. Tsai CT, Lai LP, Lin JL, Chiang FT, et al. Renin–angiotensin system gene polymorphisms and atrial fibrillation. *Circulation* 2004;109:1640–1646.
 43. Ogimoto A, Hamada M, Nakura J, Miki T, Hiwada K. Relation between angiotensin-converting enzyme II genotype and atrial fibrillation in Japanese patients with hypertrophic cardiomyopathy. *J Hum Genet* 2002;47:184–189.
 44. Gensini F, Padeletti L, Fatini C, et al. Angiotensin-converting enzyme and endothelial nitric oxide synthase polymorphisms in patients with atrial fibrillation. *Pacing Clin Electrophysiol* 2003;26:295–298.
 45. Conway DS, Buggins P, Hughes E, Lip GY. Prognostic significance of raised plasma levels of interleukin-6 and C-reactive protein in atrial fibrillation. *Am Heart J* 2004;148:462–466.
 46. Thambidorai SK, Parakh K, Martin DO, et al. Relation of C-reactive protein correlates with risk of thromboembolism in patients with atrial fibrillation. *Am J Cardiol* 2004;94:805–807.
 47. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. *J Am Coll Cardiol* 2005;45:1832–1839.
 48. Freestone B, Beevers DG, Lip GY. The renin–angiotensin–aldosterone system in atrial fibrillation: a new therapeutic target? *J Hum Hypertens* 2004;18:461–465.
 49. Hanna IR, Dudley SC Jr, King-Hageman D, et al. Lipid-lowering therapy reduces the prevalence of atrial fibrillation (Abstr). 2005 Heart Rhythm Society Scientific Sessions, May 4–7, 2005, New Orleans, LA, pp. 1–34.
 50. Merckx KL, Tieleman RG, Folkeringa RJ, et al. Use of statins is associated with reduced incidence of atrial fibrillation in patients with left ventricular hypertrophy and left atrial dilatation. Heart Rhythm Society 25th Annual Scientific Sessions, 28 May 2004, Abstract ID: 3669.
 51. Tveit A, Grundtvig M, Gundersen T, et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. *Am J Cardiol* 2004;93:780–782.
 52. Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. *Am J Cardiol* 2003;92:1379–1383.
 53. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. *Am J Cardiol* 2003;92:1343–1345.
 54. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. *Am J Cardiol* 2003;92:1343–1345.
 55. Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. *Am J Cardiol* 2003;92:1379–1383.
 56. Hanna IR, Dudley SC Jr, King-Hageman D, et al. Lipid-lowering therapy reduces the prevalence of atrial fibrillation (Abstr). 2005 Heart Rhythm Society Scientific Sessions, May 4–7, 2005, New Orleans, LA, pp. 1–34.
 57. Dernellis J, Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. *Eur Heart J* 2004;25:1100–1107.
 58. Connor WE. Importance of n-3 fatty acids in health and disease. *Am J Clin Nutr* 2000;71(suppl.):171S–175S.
 59. James MJ, Cleland LG. Dietary n-3 fatty acids and therapy for rheumatoid arthritis. *Semin Arthritis Rheum* 1997;27:85–97.
 60. Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. *Circulation* 2004;110:368–373.
 61. Frost L, Vestergaard P. n-3 Fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. *Am J Clin Nutr* 2005;81:50–54.
 62. Calo L, Bianconi L, Colivicchi F, et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. *J Am Coll Cardiol* 2005;45:1723–1728.
 63. Galaris D, Korantzopoulos P. On the molecular mechanism of metmyoglobin-catalyzed reduction of hydrogen peroxide by ascorbate. *Free Radic Biol Med* 1997;22:657–667.
 64. Carnes CA, Chung MK, Nakayama T, et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. *Circ Res* 2001;89:32–38.
 65. Li D, Benardeau A, Nattel S. Contrasting efficacy of dofetilide in differing experimental models of atrial fibrillation. *Circulation* 2000;102:104–112.
 66. Lee KW, Everett TH, Rahmutula D, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. *Circulation* 2006;114:1703–1712.
 67. Stambler BS, Fenelon G, Shepard RK, Clemo HF, Guiraudon CM. Characterization of sustained atrial tachycardia in dogs with rapid ventricular pacing-induced heart failure. *J Cardiovasc Electrophysiol* 2003;14:499–507.
 68. Okuyama Y, Miyauchi Y, Park AM, et al. High resolution mapping of the pulmonary vein and the vein of Marshall during induced atrial fibrillation and atrial tachycardia in a canine model of pacing-induced congestive heart failure. *J Am Coll Cardiol* 2003;42: 348–360.
 69. Xiao HD, Fuchs S, Campbell DJ, et al. Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. *Am J Pathol* 2004;165:1019–1032.
 70. Shi Y, Li D, Tardif JC, Nattel S. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. *Cardiovasc Res* 2002;54: 456–461.
 71. Hirayama Y, Atarashi H, Kobayashi Y, et al. Angiotensin-converting enzyme inhibitor therapy inhibits the progression from paroxysmal atrial fibrillation to chronic atrial fibrillation. *Circ J* 2005;69:671–676.
 72. Zaman AG, Kearney MT, Schecter C, Worthley SG, Nolan J. Angiotensin-converting enzyme inhibitors as adjunctive therapy in patients with persistent atrial fibrillation. *Am Heart J* 2004;147:823–827.
 73. Verheule S, Sato T, Everett Tt, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis

- caused by overexpression of TGF-beta1. *Circ Res* 2004;94:1458–1465.
74. Petrov VV, Fagard RH, Lijnen PJ. Transforming growth factor-beta(1) induces angiotensin-converting enzyme synthesis in rat cardiac fibroblasts during their differentiation to myofibroblasts. *J Renin Angiotensin Aldosterone Syst* 2000;1:342–52.
 75. Yokoyama T, Sekiguchi K, Tanaka T, et al. Angiotensin II and mechanical stretch induce production of tumor necrosis factor in cardiac fibroblasts. *Am J Physiol* 1999;276:H1968–76.
 76. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH. CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. *J Mol Cell Cardiol* 2000;32:1805–19.
 77. Carver W, Nagpal ML, Nachtigal M, Borg TK, Terracio L. Collagen expression in mechanically stimulated cardiac fibroblasts. *Circ Res* 1991;69:116–22.
 78. Riser BL, Cortes P, Heilig C, et al. Cyclic stretching force selectively up-regulates transforming growth factor-beta isoforms in cultured rat mesangial cells. *Am J Pathol* 1996;148:1915–23.
 79. Schotten U, Neuberger HR, Allessie MA. The role of atrial dilatation in the domestication of atrial fibrillation. *Prog Biophys Mol Biol* 2003;82:151–62.
 80. MacKenna D, Summerour SR, Villarreal FJ. Role of mechanical factors in modulating cardiac fibroblast function and extracellular matrix synthesis. *Cardiovasc Res* 2000;46:257–63.
 81. Nomura M, Kawano T, Nakayasu K, Nakaya Y. The effects of losartan on signal-averaged P wave in patients with atrial fibrillation. *Int J Cardiol* 2007; [Epub ahead of print]